Cart (0 Items)
Your cart is currently empty.
View ProductsCD274 / PD-L1 / B7-H1, C-His, recombinant protein
| Size | 100ug |
|---|---|
| Brand | |
| Product type | |
| Host Species | |
| Applications |
| Product name | CD274 / PD-L1 / B7-H1, C-His, recombinant protein |
|---|---|
| Origin species | Homo sapiens (Human) |
| Expression system | Eukaryotic expression |
| Molecular weight | 33.28 kDa |
| Protein delivered with Tag? | C-terminal His Tag |
| Purity estimated | >90% as determined by SDS-PAGE |
| Buffer | PBS, pH7.5 |
| Delivery condition | Dry Ice |
| Storage condition | 4°C for short term (1 week), -20°C or -80°C for long term (avoid freezing/thawing cycles; addition of 20-40% glycerol improves cryoprotection) |
| Brand | ProteoGenix |
| Host species | Mammalian cells |
| Applications | ELISA,WB |
| Fragment Type | Met1-Arg238 |
| Protein Accession | Q9NZQ7 |
| Reference | PX-P5607 |
| Note | For research use only |
Description of CD274 / PD-L1 / B7-H1, C-His, recombinant protein
General information on CD274 / PD-L1 / B7-H1, C-His, recombinant protein
CD274 / PD-L1 / B7-H1 Structure
CD274, also known as PD-L1 or B7-H1, is a type I transmembrane glycoprotein that is expressed on the surface of various cell types, including T cells, B cells, macrophages, dendritic cells, and some tumor cells. The extracellular domain of CD274 is composed of three immunoglobulin-like domains, while the intracellular domain contains a cytoplasmic tail that is important for the regulation of its activity.
CD274 / PD-L1 / B7-H1 Activity
CD274 acts as an inhibitory receptor that binds to its ligand, programmed death ligand 1 (PD-L1). This interaction between CD274 and PD-L1 results in the inhibition of T cell activation and proliferation, as well as the induction of anergy and apoptosis in T cells. In addition, CD274 can also bind to other ligands, including B7 family members, which can lead to the activation of T cells.
CD274 / PD-L1 / B7-H1 Application
CD274 has been studied extensively in the context of cancer immunotherapy, as it is often overexpressed on tumor cells.
Related products
Biosimilar
Atezolizumab Biosimilar – Anti-CD274, B7-H1, PDL1 mAb – Research Grade
PX-TA1367 300€
Biosimilar
Envafolimab Biosimilar – Anti-CD274, PD-L1, B7-H1 mAb – Research Grade
PX-TA1575 400€
Biosimilar
Cosibelimab Biosimilar – Anti-CD274, PD-L1, B7-H1 mAb – Research Grade
PX-TA1584 400€
Biosimilar
Manelimab Biosimilar – Anti-CD274, PD-L1, B7-H1 mAb – Research Grade
PX-TA1594 400€
Biosimilar
Pacmilimab Biosimilar – Anti-CD274, PD-L1, B7-H1 mAb – Research Grade
PX-TA1600 400€
Biosimilar
Acasunlimab Biosimilar – Anti-CD274;TNFRSF9 mAb – Research Grade
PX-TA1640 400€
Biosimilar
Erfonrilimab Biosimilar – Anti-CD274;CTLA4 mAb – Research Grade
PX-TA1665 400€
Biosimilar
Garivulimab Biosimilar – Anti-CD274 mAb – Research Grade
PX-TA1669 400€
Biosimilar
Sudubrilimab Biosimilar – Anti-CD274 mAb – Research Grade
PX-TA1717 400€
Biosimilar
Betifisolimab Biosimilar – Anti-CD274 mAb – Research Grade
PX-TA1816 400€
Biosimilar
Bintrafusp Biosimilar – Anti-CD274 mAb – Research Grade
PX-TA1819 400€
Biosimilar
Lesabelimab Biosimilar – Anti-CD274 mAb – Research Grade
PX-TA1858 400€
Biosimilar
Reozalimab Biosimilar – Anti-PDCD1;CD274 mAb – Research Grade
PX-TA1879 400€
Biosimilar
Retlirafusp Biosimilar – Anti-CD274 mAb – Research Grade
PX-TA1880 400€
Receptor
Reviews
Il n’y a pas encore d’avis.